AAN 2021: Nová data o dosažení NEDA u RR RS léčené okrelizumabem

(rubrika: , autor: Zdroj: Vollmer T, Freedman MS, Killestein J, Nos C, Vanopdenbosch L, Buffels R, Kadner K, Kuenzel T, Kulyk I, Hartung HP. Recently Diagnosed Early‑Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1‑Year Interim Data From the Ocrelizumab Phase IIIb ENSEMBLE Study (2261). Neurology Apr 2021, 96 (15 Supplement) 2261. Hauser SL, Kappos L, Montalban X, Chognot C, Jessop N, Pradhan A, Prajapati K, Wolinsky JS. Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1812). Neurology Apr 2021, 96 (15 Supplement) 1812., zdroj: MT)